The company said the tablet is the bioequivalent and therapeutically equivalent to the Theophylline extended-release tablets, 300 mg and 450 mg, of Alembic Pharmaceuticals Limited.
"In order to respond to an increased global demand, we plan to manufacture two billion doses of our Covid-19 vaccine in 2021 by expanding the previously expected output of 1.3 billion doses by more than 50 per cent," BioNTech said in a statement
Vaccine showed 90% efficacy in one dosing regimen when the vaccine was given as a half dose, followed by a full dose at least a month later, and another dosing regimen showed 62% efficacy when given as two full doses
